Questcor Announces First Quarter 2009 Earnings Release Date and Conference Call

* Reuters is not responsible for the content in this press release.

Mon Apr 20, 2009 6:31am EDT 

UNION CITY, Calif., April 20, 2009 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals,
Inc. (Nasdaq:QCOR) today announced that it will release financial results for
the first quarter ended March 31, 2009 on Tuesday, April 28, 2009 after the
market close. The Company will host a conference call and webcast on Tuesday,
April 28, 2009 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's
first quarter and current corporate developments. The dial-in number for the
conference call is 800-257-1836 for domestic participants and 303-262-2141 for
international participants.

A taped replay of the conference call will also be available beginning
approximately one hour after the call's conclusion and will be available for
seven days. This replay can be accessed by dialing 800-405-2236 for domestic
callers and 303-590-3000 for international callers, both using passcode
11130428#. To access the live webcast of the call, go to Questcor
Pharmaceuticals' website at www.questcor.com. An archived webcast will also be
available at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two
commercial products, H.P. Acthar(r) Gel ("Acthar") and Doral(r). Acthar
(repository corticotropin injection) is an injectable drug that is approved for
the treatment of certain disorders with an inflammatory component, including the
treatment of exacerbations associated with multiple sclerosis ("MS") and to
induce a diuresis or a remission of proteinuria in the nephrotic syndrome
without uremia of the idiopathic type or that due to lupus erythamatosus. In
addition, Acthar is not indicated for, but is used in treating patients with
infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and
opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological
disorder. Doral is indicated for the treatment of insomnia characterized by
difficulty in falling asleep, frequent nocturnal awakenings, and/or early
morning awakenings. For more information, please visit www.questcor.com.

-0-
CONTACT:  Questcor Pharmaceuticals, Inc.
          Don Bailey
          510-400-0776
          dbailey@Questcor.com

          EVC Group, Inc.
          Investors
          Doug Sherk
            415-896-6820
          Media
          Steve DiMattia
            646-201-5445
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.